How the 2529 publications in the corpus distribute across 21 application areas and five evidence tiers. The map shows how far an area has advanced in the literature; it does not indicate treatment suitability for any individual patient.
Each of the 21 application areas is counted at the evidence level of its most mature regime.
Band width shows each level's share of the 21 areas.
Rows are application areas, columns are evidence tiers. Bubble area is proportional to the publication count. Areas are sorted by clinical strength by default.
| Application area | RCT · review · guideline | Clinical study | Case series · report | Preclinical | Review · technical · other | Total | Evidence level |
|---|---|---|---|---|---|---|---|
| Skin & Cutaneous TumoursSkin & Superficial Tumours | 25 | 89 | 60 | 53 | 48 | 275 | Clinical Evidence |
| General Principles & BiophysicsBasic Science | 24 | 83 | 10 | 477 | 180 | 774 | Clinical Evidence |
| Pancreatic CancerDeep Organ Tumours | 23 | 115 | 15 | 59 | 55 | 267 | Clinical Evidence |
| Prostate & Urological TumoursUrogynaecological Tumours | 19 | 39 | 13 | 25 | 24 | 120 | Clinical Evidence |
| Liver TumoursDeep Organ Tumours | 18 | 83 | 24 | 110 | 46 | 281 | Clinical Evidence |
| Malignant MelanomaSkin & Superficial Tumours | 9 | 53 | 20 | 68 | 25 | 175 | Clinical Evidence |
| Head & Neck TumoursHead, Neck & Orbit | 6 | 34 | 14 | 8 | 12 | 74 | Clinical Evidence |
| Breast CancerDeep Organ Tumours | 4 | 32 | 12 | 44 | 15 | 107 | Clinical Evidence |
| Vulvar CancerUrogynaecological Tumours | 4 | 16 | 4 | 2 | 4 | 30 | Clinical Evidence |
| Vascular MalformationsSpecial Indications | 4 | 15 | 5 | 1 | 7 | 32 | Clinical Evidence |
| Kaposi SarcomaSkin & Superficial Tumours | 3 | 11 | 5 | 0 | 6 | 25 | Early Clinical Evidence |
| Bone & Soft Tissue SarcomasMusculoskeletal & CNS | 1 | 15 | 11 | 24 | 8 | 59 | Clinical Evidence |
| Colorectal CancerDeep Organ Tumours | 1 | 13 | 4 | 24 | 10 | 52 | Early Clinical Evidence |
| CholangiocarcinomaDeep Organ Tumours | 1 | 9 | 7 | 7 | 3 | 27 | Early Clinical Evidence |
| Lung & Peribronchial TumoursDeep Organ Tumours | 1 | 1 | 3 | 8 | 4 | 17 | Preclinical Evidence |
| Electrochemotherapy in Metastatic DiseaseSpecial Indications | 0 | 7 | 8 | 8 | 4 | 27 | Early Clinical Evidence |
| Veterinary OncologySpecial Indications | 0 | 6 | 21 | 73 | 19 | 119 | Early Clinical Evidence |
| Brain TumoursMusculoskeletal & CNS | 0 | 4 | 2 | 29 | 6 | 41 | Preclinical Evidence |
| Devices & Clinical TrialsBasic Science | 0 | 1 | 0 | 0 | 7 | 8 | Exploratory Evidence |
| Endometrial CancerUrogynaecological Tumours | 0 | 0 | 1 | 2 | 1 | 4 | Exploratory Evidence |
| Ovarian TumoursUrogynaecological Tumours | 0 | 0 | 0 | 14 | 1 | 15 | Preclinical Evidence |
Bubble size, publication count: 125100477
The strongest evidence tier in the corpus: 143 randomized trials, systematic reviews and guidelines, newest first. Click a title for the citation and full abstract.
Skin & Cutaneous Tumours · Reversible
Cutaneous metastases in patients with incurable cancer represent a significant problem as they often cause pain, discomfort, and emotional distress that affect everyday life. Finding…
Vascular Malformations · Reversible
Purpose: To review the available evidence on the effectiveness and safety of bleomycin electrosclerotherapy (BEST) for slow-flow vascular malformations. Materials and methods: A systematic…
General Principles & Biophysics · Reversible
Objectives: To systematically review the available evidence on electrochemotherapy (ECT) in pediatric patients, focusing on indications, treatment parameters, efficacy, and safety.…
Liver Tumours · Reversible
Background: Ablation therapies have attracted sustained research interest in the management of liver tumours. This study aimed to systematically map global research trends, collaboration…
General Principles & Biophysics · Reversible
Background: Pulsed electric field (PEF) ablation is a promising nonthermal tumor treatment for liver cancer, recognized for its ability to induce immune responses. However, the field has…
Prostate & Urological Tumours · Irreversible
Background: Transurethral resection of the prostate (TURP) is the gold standard for treating benign prostatic hyperplasia (BPH) but frequently causes retrograde ejaculation and bleeding.…
Liver Tumours · Irreversible
The aim of this study was to systematically pool all direct comparative evidence from two-arm studies comparing irreversible electroporation (IRE) and radiofrequency ablation (RFA) for…
Skin & Cutaneous Tumours · Irreversible
Objective The aim of this meta-analysis was to determine the efficacy and safety of percutaneous irreversible electroporation combined with immunotherapy compared with irreversible…
Skin & Cutaneous Tumours · Irreversible
Cholangiocarcinoma (CCA) is the second most common primary liver cancer and is being diagnosed with increasing frequency worldwide. We performed a systematic review on radiofrequency (RFA),…
Pancreatic Cancer · Reversible
Background: Pancreatic ductal adenocarcinoma (PDAC) is one of the most difficult cancers to treat, with a dismal 5-year survival rate of only 8-10%. This challenging prognosis highlights…
Prostate & Urological Tumours · Irreversible
Background: Laparoscopic partial nephrectomy (LPN) and laparoscopic focal therapy (LFT) have emerged as minimally invasive alternatives for managing small renal masses. Despite their…
Malignant Melanoma · Reversible
Electrochemotherapy (ECT) is a locoregional cancer treatment primarily used in the palliative management of cutaneous metastases from malignant melanoma. However, its clinical…
The tier is derived from the study type, which is itself assigned from PubMed publication types and MeSH headings, falling back to rule-based classification over the title and abstract.
The thresholds are automatic and transparent; this is not a formal GRADE assessment. An area is counted at the level of its most mature regime, and publication count is not a substitute for evidence quality.
